RecruitingNot ApplicableNCT05963698
The Fourth Left Atrial Appendage Occlusion Study
The Fourth Left Atrial Appendage Occlusion Study (LAAOS-4)
Sponsor
Hamilton Health Sciences Corporation
Enrollment
4,000 participants
Start Date
Nov 30, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- (a) Persistent or permanent atrial fibrillation OR (b) Paroxysmal atrial fibrillation in participants with a history of ischemic stroke or systemic embolism
- Increased risk of stroke, defined as a CHA2DS2-VASc stroke risk score of ≥ 4. \[Note: the acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female).\]
- Treatment with oral anticoagulants (Vitamin K agonist or factor Xa inhibitor) for at least 90 days prior to enrollment, AND no documented plan to discontinue treatment with oral anticoagulants for the expected duration of the trial.
Exclusion Criteria10
- Age \< 18 years
- Current left atrial appendage thrombus
- Prior left atrial appendage occlusion or removal (surgical or percutaneous)
- Prior percutaneous atrial septal defect or patent foramen ovale closure
- Prior atrial fibrillation ablation unless evidence of recurrent qualifying atrial fibrillation present at least 30 days following ablation
- Planned atrial fibrillation ablation within 90 days of enrollment
- Individuals being treated with direct thrombin inhibitors
- Women of childbearing potential unless they agree to employ effective birth control methods throughout the study
- Anticipated life-expectancy of \< 2 years
- Patient unable or willing to give informed consent
Interventions
DEVICEWATCHMAN device
Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
Locations(127)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05963698
Related Trials
The CONFORM Pivotal Trial
NCT0514779283 locations
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
NCT0680821732 locations
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT072275327 locations
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT0645509846 locations
Anatomical Navigation for Guided Electrophysiology in AFL and AFib
NCT072101511 location